H-ALYVDSLFFL-OH

Ref. 3D-PP43561

Información del producto

• Nombre: H-ALYVDSLFFL-OH
• Sinónimos: NH2-Ala-Leu-Tyr-Val-Asp-Ser-Leu-Phe-Phe-Leu-OH

Descripción

Peptide H-ALYVDSLFFL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-ALYVDSLFFL-OH include the following: Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer Z Molvi , RJ O'Reilly - Cancer Immunotherapies: Solid Tumors and , 2022 - Springerhttps://link.springer.com/chapter/10.1007/978-3-030-96376-7_4 War and Remission: Phosphopeptides, Fusion Proteins, and Predictive Biomarkers in Cancer Immunotherapy Z Molvi - 2023 - search.proquest.comhttps://search.proquest.com/openview/2d40a6573987b63d60263c9e2cd6ec47/1?pq-origsite=gscholar&cbl=18750&diss=y Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro YS Mohamed , D Dunnion, I Teobald, R Walewska - Immunobiology, 2012 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0171298511002610 NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine SM Pollack , Y Li, MJ Blaisdell, EA Farrar, J Chou - PloS one, 2012 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0032165 Identification of Cross-Reactive Targets of TCR-Based Therapeutic Agents within the Human Proteome RS Gejman , T Dao, DA Scheinberg - Blood, 2017 - ashpublications.orghttps://ashpublications.org/blood/article/130/Supplement%201/3188/114814 Prospective identification of cross-reactive human peptide-MHC ligands for T cell receptor based therapies RS Gejman , MG Klatt , A Chang , HF Jones, CY Oh - BioRxiv, 2018 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/267047.abstract Identification of the targets of T-cell receptor therapeutic agents and cells by use of a high-throughput genetic platform RS Gejman , HF Jones, MG Klatt , AY Chang - Cancer immunology , 2020 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/8/5/672/470110 The Fault is in Our TCRS: Searching for on and Off-targets in T Cell Receptor Based Therapies RS Gejman - 2018 - search.proquest.comhttps://search.proquest.com/openview/f4f6171fe52cecfd9f547336cb14ce5b/1?pq-origsite=gscholar&cbl=18750 A systematic review of potential immunotherapies targeting PRAME in retinoid resistant oral potentially malignant disorders and oral cancer R Dwivedi , D Mehrotra , S Chandra - Current Molecular , 2022 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cmm/2022/00000022/00000008/art00006 Peptide vaccines for patients with acute myeloid leukemia M Schmitt , R Casalegno-Garduno, X Xu - Expert Review of , 2009 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1586/erv.09.90 Dendritic Cells (DC) Generated from AML Blasts Express Leukemia Associated Antigens Eliciting Specific Cytotoxic T Cell Responses in the Autologous Host L Li, P Reinhardt, I Hus, J Rolinski , A Dmoszynska - Blood, 2004 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497118657106 Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens L Li, P Reinhardt, A Schmitt, TFE Barth - Cancer Immunology , 2005 - Springerhttps://link.springer.com/article/10.1007/s00262-004-0631-8 Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts L Li, K Giannopoulos, P Reinhardt - International , 2006 - spandidos-publications.comhttps://www.spandidos-publications.com/ijo/28/4/855 Characterization of dendritic cells generated from acute myeloid leukemia blasts as a potential cancer vaccine L Li - 2005 - oparu.uni-ulm.dehttps://oparu.uni-ulm.de/xmlui/handle/123456789/582 Efficient identification of novel Hla-A* 0201-Presented Cytotoxic T Lymphocyte epitopes in the widely expressed tumor antigen prame by Proteasome-Mediated JH Kessler, NJ Beekman, SA Bres-Vloemans - The Journal of , 2001 - rupress.orghttps://rupress.org/jem/article-abstract/193/1/73/20096 Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches J Greiner, M Schmitt , L Li, K Giannopoulos, K Bosch - Blood, 2006 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/108/13/4109/6594 Antigen targets for the development of immunotherapies in leukemia J Bauer, A Nelde , T Bilich , JS Walz - International Journal of Molecular , 2019 - mdpi.comhttps://www.mdpi.com/1422-0067/20/6/1397 A high-avidity T-cell receptor redirects natural killer T-cell specificity and outcompetes the endogenous invariant T-cell receptor E Landoni , CC Smith , G Fuca , Y Chen , C Sun - Cancer immunology , 2020 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/8/1/57/469564 Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia C Quintarelli, G Dotti, B De Angelis - Blood, The Journal , 2008 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/112/5/1876/25541 A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens AY Chang , T Dao, RS Gejman - The Journal of , 2017 - Am Soc Clin Investighttps://www.jci.org/articles/view/92335 A TCR Mimic Antibody Targets Immunoproteasome-Regulated Prame Peptide/HLA-I Antigens for Cancer Therapy AY Chang - 2018 - search.proquest.comhttps://search.proquest.com/openview/f37a6587e3a637d370106221151ecc73/1?pq-origsite=gscholar&cbl=18750 Dendritic cell vaccines for leukemia patients A Schmitt, I Hus, M Schmitt - Expert review of anticancer therapy, 2007 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1586/14737140.7.3.275

• Marca: Biosynth